Senior NIH scientist faulted

A top NIH official gave Pfizer thousands of samples in exchange for $285,000 in consulting fees, according to a Congressional report released yesterdayTrey Sunderland, chief of the Geriatric Psychiatry Branch of the National Institute of Mental Health (NIMH), improperly transferred 3,200 vials of human spinal fluid and 388 tubes of plasma collected for Alzheimer?s research, the 25-page study by the House Energy and Commerce Subcommittee on Oversight and Investigations said.Sunderland received more than $600,000 in outside consulting and speaking fees from Pfizer from 1998 to 2004 without prior government disclosure or approval. A review by NIH?s Office of Management Assessment found that Sunderland ?engaged in serious misconduct, in violation of HHS ethics rules and Federal law and regulation,? the report stated. Sunderland has not been charged with any crime and remains an NIH employee and member of the Public Health Service Corps.Obtaining the NIH tissue samples ? a ?unique historical collection? from a multi-year longitudinal study of more than 500 Alzheimer?s patients and their families -- was the ?primary reason? behind Pfizer?s interest in collaborating with Sunderland in 1998, the committee report stated. Procuring the tissue samples alone cost the government $6.4 million, reported committee staffers, who spent a year investigating the matter. There was ?no evidence? that Pfizer was aware of any questionable activity on Sunderland's part, the report noted. Neither Sunderland nor his attorney, Robert Muse, responded to requests from The Scientist yesterday for comment. The report was released yesterday at the start of two days of subcommittee hearings on NIH?s handling of human tissue samples. More than 660 NIH labs maintain repositories of human body fluids and tissues, yet the agency lacks a formal inventory control or tracking system and has ?no uniform, centralized, and mandatory authority? for handling these samples, the report said. ?It would really be a shame if we find out that the National Institutes of Health has more control over its paper clips and trash cans than it has over its human tissue samples,? said committee chairman Rep. Joe Barton (R-Texas) in a statement released yesterday.The House investigation into Sunderland?s tissue sample transfer began in April 2005 after Susan Molchan, program director for Alzheimer?s disease research at the National Institute of Aging, raised concerns ?about what happened to the more than 95% of the unused spinal fluid samples left in the freezer? at NIMH, according to the committee report. Sunderland?s outside activities first came to light during a 2004 subcommittee investigation into consulting practices at NIH. Following a series of media reports and congressional inquiries, NIH banned all outside consulting with biotech, pharmaceutical, and medical devices companies in February 2005. Ted Agres tagres@the-scientist.comLinks within this articleTrey Sunderland http://intramural.nimh.nih.gov/research/pi/pi_sunderland.htmlStaff Report of the House Committee on Energy and Commerce. http://energycommerce.house.gov/108/home/staff%20report.pdfT. Agres, ?NIH needs ?drastic changes,? The Scientist, June 23, 2004 http://www.the-scientist.com/article/display/22245/T. Agres, ?NIH bans all consulting,? The Scientist, February 2, 2005 http://www.the-scientist.com/article/display/22586/

Senior NIH scientist faulted

The Scientist ARCHIVES

Become a Member of

Meet the Author

Ted Agres

Related Research Resources

Nergal Networks: Where Friendship Meets Infection

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Unraveling Complex Biology with Five-Dimensional Multiomics

Resurrecting Plant Defense Mechanisms to Avoid Crop Pathogens

Seeing and Sorting with Confidence

Streamlining Microbial Quality Control Testing

Products

Product News

Agilent Unveils the Next Generation in LC-Mass Detection: The InfinityLab Pro iQ Series

Pioneering Cancer Plasticity Atlas will help Predict Response to Cancer Therapies

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease

How Alderley Analytical are Delivering eXtreme Robustness in Bioanalysis